Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms of Radiprodil in Patients With Tuberous Sclerosis Complex (TSC) or Focal Cortical Dysplasia (FCD) Type II
Conditions
Interventions
Radiprodil
Locations
18
Australia
Queensland Children Hospital
South Brisbane, Australia
University Hospitals Leuven, Pediatric Neurology
Leuven, Belgium
Alberta Children's Hospital
Calgary, Canada
The Hospital for Sick Children (Sick Kids)
Toronto, Canada
IRCCS Istituto Giannina Gaslini
Genoa, Liguria, Italy
AOU Meyer
Florence, Tuscany, Italy
Start Date
July 10, 2024
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2028
Last Updated
April 1, 2026
NCT07369505
NCT06879665
NCT04198181
NCT06975605
NCT05604170
NCT06789419
Lead Sponsor
GRIN Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions